<table border="0" cellpadding="0" cellspacing="0" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 4: Clinically Relevant Interactions Affecting Omeprazole When Co-Administered with Other Drugs</caption>
<colgroup>
<col width="19.94%"></col>
<col width="80.06%"></col>
</colgroup>
<tbody>
<tr stylecode="Botrule">
<td align="justify" colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">CYP2C19 or CYP3A4 Inducers</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Decreased exposure of omeprazole when used concomitantly with strong inducers <content stylecode="italics">[see </content>
<content stylecode="italics">
<content stylecode="italics">
<content stylecode="underline">
<linkhtml href="#Section_12.3">Clinical Pharmacology (12.3)</linkhtml>
</content>
</content>].</content>
<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">
<content stylecode="underline">St. John’s Wort, rifampin:</content> Avoid concomitant use with omeprazole <content stylecode="italics">[see <content stylecode="italics">
<content stylecode="underline">
<linkhtml href="#Section_5.16">Warnings and Precautions (5.9)</linkhtml>
</content>
</content>].</content>
<br/>
<content stylecode="underline">Ritonavir-containing products:</content> see prescribing information for specific drugs.<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">CYP2C19 or CYP3A4 Inhibitors</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Increased exposure of omeprazole <content stylecode="italics">[see <content stylecode="italics">
<content stylecode="underline">
<linkhtml href="#Section_12.3">Clinical Pharmacology (12.3)</linkhtml>
</content>
</content>].</content>
<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr>
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">
<content stylecode="underline">Voriconazole:</content> Dose adjustment of omeprazole is not normally required. However, in patients with Zollinger-Ellison syndrome, who may require higher doses, dose adjustment may be considered.<br/> <br/>See prescribing information for voriconazole.<content stylecode="bold"></content>
<br/>
</td>
</tr>
</tbody>
</table>